INS and Hypoglycemia: Overall, HbA1c in the sotagliflozin group fell by 0.46%, associated with a decrease in weight (−2.98 kg), systolic blood pressure (−3.5 mm Hg) and average daily bolus insulin dose (−2.8 units) without an increase in hypoglycaemia; if anything, the rate of documented hypoglycaemia (3.1 mmol/L or lower) was significantly lower in the sotagliflozin group.